China’s New Robot Surgery Reimbursement Rules Change the Economics of Surgical Robots

China’s latest medical-insurance reforms make robot-assisted surgery easier to price and more visible in episode-based payment. The important change is not a single national reimbursement amount. It is the connection between a nationally standardized charging framework and more specific DRG/DIP payment groups—a combination that can reduce the risk of treating a higher-cost robotic case as if it were a conventional operation.196

The mismatch the policies are designed to reduce

Hospitals need two things for a robotic procedure to be economically workable:

1. A recognized service-price item that permits charging for the robot’s contribution to surgery.
2. A payment classification that does not bury the added resource use inside the same episode-payment bucket as a non-robotic case.

China’s National Healthcare Security Administration (NHSA) addressed the first issue in January 2026. Its pricing-item guideline established three categories for surgical mechanical-arm assistance—navigation, participatory execution, and precision execution—based on the technology’s level of participation and clinical value. The framework does not divide items by surgical approach, body part, or whether a system is domestic or imported. It uses a coefficient-based approach tied to the main surgery, with deeper participation and greater precision eligible for a higher coefficient.19

DRG/DIP 3.0 addresses the second issue. Released on September 2, 2026, the new grouping schemes refine robot-assisted surgery in national payment grouping. The DRG framework contains nine robot-assisted surgical groups, while DIP includes relevant robot-assisted combinations for selected indications.615

In practical terms, the first policy answers how robotic assistance may be priced; the second improves the prospect that the payer’s episode-based settlement can distinguish an eligible robotic case from a conventional one. That alignment creates a more credible path to covering the additional resources associated with robotic surgery.196

Why dedicated payment groups matter for hospitals

DRG and DIP systems are designed to pay hospitals based on case groupings rather than simply reimbursing every input separately. If a robot-assisted operation with expensive instruments and technical demands were grouped and paid the same way as a comparable conventional operation, hospitals could face a financial disincentive to use the robot even where it was clinically appropriate.

The policy change does not remove cost pressure. Robotic programs still must absorb the economics of equipment ownership, servicing, specialized consumables, training, and operating-room workflow. But a separate or more tailored payment grouping gives local payers a basis to reflect differences in resource use and technical intensity rather than making the robotic contribution invisible within a standard bundle.839

The stakes are substantial because disease-based payment is now the dominant reimbursement mechanism. In 2025, DRG/DIP payment accounted for 91.8% of insured inpatient discharges nationwide.37 For hospitals, therefore, a charge item on its own is not enough: the settlement logic for the inpatient episode is likely to shape the business case for most robotic procedures.

What DRG/DIP 3.0 actually covers

The reform is meaningful, but it is not universal coverage for every robotic procedure.

Under DRG 3.0, the nine robot-assisted groups span high-use surgical areas including orthopedics, urology, gynecology, thoracic surgery, and gastrointestinal surgery. Reported groupings include spinal, joint and femur procedures; kidney and prostate procedures; selected gynecologic operations; lung surgery; and major intestinal surgery.6

DIP treatment is narrower in an important respect. Robot-assistance codes are treated as related or auxiliary operations rather than the principal surgery; the relevant combinations include selected orthopedic conditions and procedures, such as joint replacement and fractures.615

That means hospitals and manufacturers should assess reimbursement indication by indication. A robot system’s regulatory authorization or technical capabilities do not by themselves establish a favorable payment pathway for every procedure it can perform.

National framework, local economics

The January guideline standardizes the architecture of price items nationally, but it does not set one nationwide robot-surgery fee. NHSA guidance calls on provincial authorities to develop provincial price benchmarks, while areas with pricing authority determine actual execution prices within that structure.23

Hunan illustrates how local implementation can differ. Its 2026 policy uses a main-surgery price base multiplied by tiered additional-charge coefficients for surgical mechanical arms, with floor and ceiling prices. The NHSA described ranges of ¥1,800–¥3,600 for navigation, ¥5,000–¥12,000 for participatory execution, and ¥16,000–¥26,000 for precision execution in that local implementation.32

Nor does a dedicated group guarantee a profitable robotic program. Local payment weights and rates, coding accuracy, utilization, case mix, procurement terms, consumable costs, and operational efficiency will all affect a hospital’s result. The policy provides a clearer payment signal, not an automatic margin.

Implications for China’s domestic surgical-robot makers

For suppliers, the reforms potentially reduce a major adoption barrier. Hospitals considering a system can more plausibly link the robot’s use to both a recognized service-price framework and an episode-payment classification. If local implementation is workable, that can support utilization after installation—and, in turn, recurring demand for instruments, maintenance, training, and upgrades rather than only a one-time capital-equipment sale.196

The national pricing structure is also brand-neutral: classification depends on the robot’s role in the procedure rather than whether it is domestic or imported.19 That does not guarantee a commercial advantage for Chinese manufacturers, but it means domestic systems need not rely on a separate pricing category to participate in the framework.

Competition is already broadening. Publicly disclosed 2025 tender awards covered 90 laparoscopic surgical robot systems from nine manufacturers; eight Chinese manufacturers recorded tender wins, according to MedRobot and MedChina’s analysis.36

The next competitive challenge: repeat procedures

The strategic test now moves beyond regulatory clearance and equipment placement. Sustainable economics require repeat, correctly coded, reimbursable procedures at sufficient volume to support a hospital’s robotic program.

That raises the value of capabilities beyond hardware:

• surgeon training and clinical adoption support;
• dependable field service and maintenance;
• reliable, competitively priced instrument supply;
• operating-room workflow integration;
• evidence and coding support for covered indications; and
• disciplined expansion into procedures where clinical use and local payment rules align.

The central takeaway is straightforward: China has improved the bridge between charging for robotic assistance and paying for robot-assisted episodes. The bridge is not a blanket reimbursement guarantee. Its commercial effect will be determined locally—and the manufacturers best positioned to benefit will be those that help hospitals turn installed systems into safe, sustained procedure volume.19623